

BAN2401								
CATEGORY	PLACEBO (N=30)	2.5 mg/kg BI-WEEKLY (N=1)	5 mg/kg MONTHLY (N=4)	5 mg/kg BI-WEEKLY (N=17)	10 mg/kg MONTHLY (N=43)	10 mg/kg BI-WEEKLY (N=26)	TOTAL (N=91)	COMBINED TOTAL (N=121)
AGE (YEAR) ^a								
n	30	1	4	17	43	26	91	121
MEAN (SD)	69.67 (7.967)	50.00 (NA)	73.50 (8.021)	70.12 (6.836)	71.00 (7.300)	74.65 (7.116)	71.76 (7.615)	71.24 (7.723)
SEX, n (%)								
MALE	14 (46.7)	1 (100.0)	1 (25.0)	6 (35.3)	27 (62.8)	13 (50.0)	48 (52.7)	62 (51.2)
FEMALE	16 (53.3)	0	3 (75.0)	11 (64.7)	16 (37.2)	13 (50.0)	43 (47.3)	59 (48.8)
RACE, n (%)								
WHITE	22 (73.3)	1 (100.0)	4 (100.0)	13 (76.5)	32 (74.4)	24 (92.3)	74 (81.3)	96 (79.3)
BLACK OR AFRICAN AMERICAN	0	0	0	0	1 (2.3)	0	1 (1.1)	1 (0.8)
CHINESE	1 (3.3)	0	0	0	0	0	0	1 (0.8)
JAPANESE	6 (20.0)	0	0	3 (17.6)	8 (18.6)	2 (7.7)	13 (14.3)	19 (15.7)
OTHER ASIAN	1 (3.3)	0	0	0	0	0	0	1 (0.8)
OTHER	0	0	0	1 (5.9)	2 (4.7)	0	3 (3.3)	3 (2.5)
MISSING	0	0	0	0	0	0	0	0
REGION, n (%)								
NORTH AMERICA	22 (73.3)	1 (100.0)	4 (100.0)	10 (58.8)	33 (76.7)	23 (88.5)	71 (78.0)	93 (76.9)
WESTERN EUROPE	1 (3.3)	0	0	3 (17.6)	1 (2.3)	1 (3.8)	5 (5.5)	6 (5.0)
ASIA	7 (23.3)	0	0	4 (23.5)	9 (20.9)	2 (7.7)	15 (16.5)	22 (18.2)
APOE4 CARRIER STATUS, n (%)								
POSITIVE	21 (70.0)	1 (100.0)	4 (100.0)	17 (100.0)	43 (100.0)	2 (7.7)	67 (73.6)	88 (72.7)
HETEROZYGOUS	19 (63.3)	1 (100.0)	3 (75.0)	13 (76.5)	32 (74.4)	2 (7.7)	51 (56.0)	70 (57.9)
HOMOZYGOUS	2 (6.7)	0	1 (25.0)	4 (23.5)	11 (25.6)	0	16 (17.6)	18 (14.9)
NEGATIVE	9 (30.0)	0	0	0	0	24 (92.3)	24 (26.4)	33 (27.3)
DISEASE STAGE, n (%)								
MCI DUE TO AD	20 (66.7)	1 (100.0)	4 (100.0)	9 (52.9)	24 (55.8)	17 (65.4)	55 (60.4)	75 (62.0)
MILD AD	10 (33.3)	0	0	8 (47.1)	19 (44.2)	9 (34.6)	36 (39.6)	46 (38.0)
ONGOING BASELINE TREATMENT WITH AChEs AND/OR MEMANTINE								
NO	16 (53.3)	1 (100.0)	3 (75.0)	8 (47.1)	22 (51.2)	14 (53.8)	48 (52.7)	64 (52.9)
YES	14 (46.7)	0	1 (25.0)	9 (52.9)	21 (48.8)	12 (46.2)	43 (47.3)	57 (47.1)

FIG. 1




FIG. 2




FIG. 3

PET SUVR	Δ CORE BL TO CORE 18m	Δ CORE 18m TO OLE BL	Δ OLE BL TO OLE 12m
PLACEBO (n=8)	0.04	0.03	-0.26
10 MONTHLY (n=13)	-0.24	0.04	-0.11
10 BIWEEKLY (n=5)	-0.31	0.03	-0.05
PLASMA A β 42/40 RATIO	Δ CORE BL TO CORE 18m	Δ CORE 18m TO OLE BL	Δ OLE BL TO OLE 12m
PLACEBO (n=8)	-0.005	0	0.012
10 MONTHLY (n=13)	0.007	-0.003	0.005
10 BIWEEKLY (n=5)	0.013	-0.007	0.002

FIG. 4




FIG. 5




FIG. 6




FIG. 7




FIG. 8




FIG. 9




FIG. 10

11/37

FROM
FIG. 10





FIG. 10 (CONT.)



FROM
FIG. 11





FIG. 11 (CONT.)

14/37

DOSE

- 01: 10 mg/kg Q2W FOR 42 MONTHS
02: 10 mg/kg Q2W FOR 18 MONTHS + 24 MONTHS TREATMENT DISCONTINUATION
03: 10 mg/kg Q2W FOR 18 MONTHS + 10 mg/kg Q4W FOR 24 MONTHS
04: 10 mg/kg Q2W FOR 18 MONTHS + 10 mg/kg Q3M FOR 24 MONTHS

LINE AND SHADED AREA SHOWS PREDICTED MEDIAN AND 95% CI, RESPECTIVELY

**FIG. 12**




FIG. 13




FIG. 14




FIG. 15





FIG. 16

**FIG. 17**





FIG. 18

**FIG. 19**




FIG. 20




FIG. 21




FIG. 22





FIG. 23






FIG. 25




FIG. 26




FIG. 27

30/37




FIG. 28




FIG. 29




FIG. 30




FIG. 31




FIG. 32






FIG. 33



THICK LINE AND SHADED AREA SHOW PREDICTED MEDIAN AND 95% CI, RESPECTIVELY. BLACK DOTTED LINE IN SUVr PLOT REPRESENTS SUVr= 1.17, INDICATING AMYLOID NEGATIVE LINE. FOR SUVr, BASELINE SUVr= 1.38 (MEDIAN OF STUDY 201) WAS ASSUMED

FIG. 34



BLACK DOTTED LINE IN SUVR PLOT REPRESENTS SUVR = 1.17, INDICATING AMYLOID NEGATIVE LINE, FOR SUVR, LOWER BOUND SUVR = 1.0 (THEORETICAL LOWER BOUND) WAS ASSUMED

FIG. 35